Proinsulin C-peptide: Friend or foe in the development of diabetes-associated complications?

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1283-1288

  Nordquist, Lina ^a   Johansson, M ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C peptide; Cardiovascular; Diabetes; Proinsulin

Indexed keywords

C PEPTIDE; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CELL SURVIVAL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; HEART PROTECTION; HUMAN; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SYNTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; APOPTOSIS; BLOOD VESSELS; C-PEPTIDE; CARDIOVASCULAR DISEASES; CELL PROLIFERATION; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; IMMUNE SYSTEM; NEOVASCULARIZATION, PHYSIOLOGIC; NEURONS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 60249084283     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Al-Rasheed NM, Willars GB, Brunskill NJ. 2006. C-peptide signals via Galpha i to protect against TNF-alpha-mediated apoptosis of opossum kidney proximal tubular cells. J Am Soc Nephrol, 17:986-95.
2. Brand K, Page S, Rogler G, et al. 1996. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest, 97:1715-22.
3. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414:813-20.
4. Castellani P, Viale G, Dorcaratto A, et al. 1994. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer, 59:612-8.
5. Chakrabarti S, Khan ZA, Cukiernik M, et al. 2004. C-peptide and retinal microangiopathy in diabetes. Exp Diabesity Res, 5:91-6.
6. [DCCT] The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 329:977-86.
7. Denk A, Wirth T, Baumann B. 2000. NF-kappaB transcription factors: critical regulators of hematopoiesis and neuronal survival. Cytokine Growth Factor Rev, 11:303-20.
8. De La Tour DD, Raccah D, Jannot MF, et al. 1998. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia, 41:1080-4.
9. DiPetrillo K, Gesek FA. 2004. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol, 24:352-9.
10. Fioretto P, Steffes MW, Sutherland DE, et al. 1998. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med, 339:69-75.
11. Fiorina P, Folli F, Zerbini G, et al. 2003. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol, 14:2150-8.
12. Forst T, Kunt T, Pohlmann T, et al. 1998a. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest, 101:2036-41.
13. Forst T, Kunt T, Pfutzner A, et al. 1998b. New aspects on biological activity of C-peptide in IDDM patients. Exp Clin Endocrinol Diabetes, 106:270-6.
14. Grunberger G, Qiang X, Li Z, et al. 2001. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia, 44:1247-57.
15. Hansen A, Johansson BL, Wahren J, et al. 2002. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes, 51:3077-82.
16. Hasegawa G, Nakano K, Sawada M, et al. 1991. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int, 40:1007-12.
17. Heliövaara MK, Teppo AM, Karonen SL, et al. 2005. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 7:729-36.
18. Hotamisligil GS. 1999a. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes, 107:119-25.
19. Hotamisligil GS. 1999b. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intenn Med, 245:621-5.
20. Hotamisligil GS, Murray DL, Choy LN, et al. 1994. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A, 91:4854-8.
21. Huang DY, Richter K, Breidenbach A. 2002. Human C-peptide acutely lowers glomerular hyperfiltration and proteinuria in diabetic rats: a dose-response study. Naunyn Schmiedebergs Arch Pharmacol, 365:67-73.
22. Ido Y, Vindigni A, Chang K, et al. 1997. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science, 277:563-6.
23. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, et al. 1989. Features of endothelial dysfunction in early diabetic nephropathy. Lancet, 1:461-3.
24. Johansson BL, Linde B, Wahren J. 1992. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia, 35:1151-8.
25. Johansson BL, Borg K, Fernqvist-Forbes E. 2000. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med, 17:181-9.
26. Johansson BL, Wahren J, Pernow J. 2003. C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism. Am J Physiol Endocrinol Metab, 285:E864-70.
27. Kalantarinia K, Awad AS, Siragy HM. 2003. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int, 64:1208-13.
28. Karelina TV, Eisen AZ. 1998. Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors. Cancer Detect Prev, 22:438-44.
29. Khan ZA, Cukiernik M, Gonder JR, et al. 2004. Oncofetal fibronectin in diabetic retinopathy. Invest Ophthalmol Vis Sci, 45:287-95.
30. Kitamura T, Kimura K, Jung BD, et al. 2001. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem J, 355:123-9.
31. Kitazawa M, Shibata Y, Hashimoto S, et al. 2006. Proinsulin C-peptide stimulates a PKC/IkappaB/NF-kappaB signaling pathway to activate COX-2 gene transcription in Swiss 3T3 fibroblasts. J Biochem, 139:1083-8.
32. Kobayashi Y, Naruse K, Hamada Y, et al. 2005. Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia, 48:2396-401.
33. Kunt T, Schneider A, Pfutzner A, et al. 1999. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus. Diabetologia, 42:465-71.
34. Langer S, Born F, Breidenbach A, et al. 2002. Effect of C-peptide on wound healing and microcirculation in diabetic mice. Eur J Med Res, 7:502-8.
35. Lee TC, Barshes NR, Agee EE. 2006. The effect of whole organ pancreas transplantation and PIT on diabetic complications. Curr Diab Rep, 6:323-7.
36. Li ZG, Zhang W, Sima AA. 2003. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev, 19:375-85.
37. Li ZG, Sima AA. 2004. C-peptide and central nervous system complications in diabetes. Exp Diabesity Res, 5:79-90.
38. Maezawa Y, Yokote K, Sonezaki K, et al. 2006. Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev, 22:313-22.
39. Manzella D, Ragno E, Abbatecola AM, et al. 2003. Residual C-peptide secretion and endothelial function in patients with Type II diabetes. Clin Sci (Lond), 105:113-18.
40. Marx N, Walcher D, Raichle C, et al. 2004. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol, 24:540-5.
41. Moriwaki Y, Inokuchi T, Yamamoto A, et al. 2007. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol, 44:215-8.
42. Nakamura T, Fukui M, Ebihara I, et al. 1993. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes, 42:450-6.
43. Navarro JF, Mora C, Maca M, et al. 2003. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis, 42:53-61.
44. Nordquist L, Moe E, Sjoquist M. 2007. The C-peptide fragment EVARQ reduces glomerular hyperfiltration in streptozotocin-induced diabetic rats. Diabetes Metab Res Rev, 23:400-5.
45. O'Neill LA, Kaltschmidt C. 1997. NF-kappaB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci, 20:252-8.
46. Pieper GM, Riaz-ul-Haq. 1997. Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol, 30:528-32.
47. Samnegard B, Jacobson SH, Jaremko G, et al. 2001. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int, 60:1258-65.
48. Samnegard B, Jacobson SH, Johansson BL, et al. 2004. C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant, 19:1385-91.
49. Sari R, Balci MK. 2005. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc, 97:1113-8.
50. Scalia R, Coyle KM, Levine BJ, et al. 2000. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J, 14:2357-64.
51. Schmidt C, Hocherl K, Schweda F, et al. 2007. Regulation of renal sodium transporters during severe inflammation. J Am Soc Nephrol, 18:1072-83.
52. Shapiro AM, Ricordi C, Hering BJ, et al. 2006. International trial of the Edmonton protocol for islet transplantation. N Engl J Med, 355:1318-30.
53. Sima AA, Zhang W, Grunberger G. 2004. Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res, 5:65-77.
54. Sjoquist M, Huang W, Johansson BL. 1998. Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int, 54:758-64.
55. Steffes MW, Sibley S, Jackson M, et al. 2003. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care, 26:832-6.
56. Stridh S, Sällström J, Fridén M, et al. 2008. C-peptide normalizes glomerular filtration rate in hyperfiltrating streptozotocin-induced diabetic rats. In vivo measurements in conscious rats. Adv Exp Med Biol, In press.
57. Sugimoto H, Shikata K, Wada J, et al. 1999. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia, 42:878-86.
58. Tsimaratos M, Roger F, Chabardes D, et al. 2003. C-peptide stimulates Na+,K+-ATPase activity via PKC alpha in rat medullary thick ascending limb. Diabetologia, 46:124-31.
59. Walcher D, Aleksic M, Jerg V, et al. 2004. C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes, 53:1664-70.
60. Walcher D, Babiak C, Poletek P, et al. 2006. C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res, 99:1181-7.
61. Witztum JL, Steinberg D. 1991. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest, 88:1785-92.
62. Yerneni KK, Bai W, Khan BV, et al. 1999. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes, 48:855-64.
63. Young LH, Ikeda Y, Scalia R, et al. 2000. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol, 279:H1453-9.
64. Zhong Z, Davidescu A, Ehren I, et al. 2005. C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells. Diabetologia, 48:187-97.
65. Zhong Z, Kotova O, Davidescu A, et al. 2004. C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci, 61:2782-90.